Skip Navigation

Center for Immunization Research

Left Background
 

Enteric Bacterial Infections Selected Publications
Darsley MJ, Chakraborty S, DeNearing B, Sack DA, Feller A, Buchwaldt C, Bourgeois AL, Walker R, Harro CD..The oral, live attenuated enterotoxigenic Escherichia coli vaccine ACE527 reduces the incidence and severity of diarrhea in a human challenge model of diarrheal disease .Clin Vaccine Immunol. 2012 Dec;19(12):1921-31.

Harro, CD, Betts RF, Hartzel JS, Onorato MT, Lipka J, Smugar SS, Kartsonis NA. The immunogenicity and safety of different formulations of a novel Staphylococcus aureus vaccine (V710): Results of two Phase I studies. Vaccine. 2011 Dec 20; Epub ahead of print.

Atmar RL, Bernstein DI, Harro CD, Al-Ibrahim MS, Chen WH, Ferreira J, Estes MK, Graham DY, Opekun AR, Richardson C, Mendelman PM. Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med. 2011 Dec 8;365(23):2178-87.

Harro C, Sack D, Bourgeois AL, Walker R, DeNearing B, Feller A, Chakraborty S, Buchwaldt C, Darsley MJ. A combination vaccine consisting of three live attenuated enterotoxigenic Escherichia coli strains expressing a range of colonization factors and heat-labile toxin subunit B is well tolerated and immunogenic in a placebo-controlled double-blind phase I trial in healthy adults. Clin Vaccine Immunol. 2011 Dec 18;(12)2118-27. Epub 2011 Oct 12.

Harro C, Chakraborty S, Feller A, DeNearing B, Cage A, Ram M, Lundgren A, Svennerholm AM, Bourgeois AL, Walker RI, Sack DA. Refinement of a human challenge model for evaluation of enterotoxigenic Escherichia coli vaccines. Clin Vaccine Immunol. 2011 Oct; 18(10):1719-27. Epub 2011 Aug 18.

Harro C, Betts, R, Orenstein W, Kwak EJ, Greenberg HE, Onorato MT, Hartzel J, Lipka J, DiNubile MJ, Kartsonis N. Safety and immunogenicity of a novel Staphylococcus aureus vaccine results from the first study of the vaccine dose range in humans. Clin Vaccine Immunol. 2010 Dec;17(12);1868-74. Epub 2010 Oct 13.

Lyon C E; Sadigh K S; Carmolli M P; Harro C; Sheldon E; Lindow J C; Larsson C J; Martinez T; Feller A; Ventrone C H; Sack D A; DeNearing B; Fingar A; Pierce K; Dill E A; Schwartz HI; Beardsworth E E; Kilonzo B; May J P; Lam W; Upton A; Budhram R; Kirkpatrick BD. In a randomized, double-blinded, placebo-controlled trial, the single oral dose typhoid vaccine, M01ZH09, is safe and immunogenic at doses up to 1.7 x 10(10) colony-forming units Vaccine 2010;28(20):3602-

McKenzie R, Darsley M, Thomas N, Randall R, Carpenter C, Forbes E, Finucane M, Sack RB, Hall E, Bourgeois AL. A double-blind, placebo-controlled trial to evaluate the efficacy of PTL-003, an attenuated enterotoxigenic E. coli (ETEC) vaccine strain, in protecting against challenge with virulent  ETEC Vaccine 2008 -26(36)4731-9.

Frech SA, Dupont HL, Bourgeois AL, McKenzie R, Belkind-Gerson J, Figueroa JF, et al. Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. Lancet. 2008; 371(9629):2019-25.

McKenzie R, Venkatesan MM, Wolf MK, Islam D, Grahek S, Jones AM, Bloom A, Taylor DN, Hale TL, Bourgeois AL. Safety and immunogenicity of WRSd1, a live attenuated Shigella dysenteriae type 1 vaccine candidate. Vaccine. 2008; 26(26):3291-6.
 

McKenzie R, Clemens JD.(2008)  Natural Immunity with Exposure.  In Travelers’ Diarrhea, 2nd edition. Ericson CD, Dupont HL, Steffen R (eds.), BC Decker Inc., Hamilton, Ontario, Canada. (22):210-14

Taylor DN, Bourgeois AL, Erisson CD, Steffen R, Jiang ZD, Haake R, Dupont HL, and the Rifaximin study group. A randomized, double-blind, multicenter study of Rifaximin compared to placebo and with ciprofloxacin in the treatment of Traveler’s diarrhea. Amer Trop Med Hyg. 2006; 74:1060-1066.

Kirkpatrick BD, McKenzie R, O’Neill JP, Larsson CJ, Bourgeois AL, Shimko J, Bentley M, Makin J, Chatfield S, Hindle Z, Fidler C, Robinson BE, Ventrone CH, Bansal N, Carpenter CM, Kutzko D, Hamlet S, LaPointe C,Taylor DN. 2005.  Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers. Vaccine. 2006; 24:116-123.

Sack DA, Shimko J, Torres O, Bourgeois AL, Francia DS, Gustafsson B, Karnell A, Nyquist I, Svennerholm AM. Randomised, double-blind, safety and efficacy of a killed oral vaccine for enterotoxigenic E. coli diarrhoea of  travellers to Guatemala and Mexico. Vaccine. 2007; 25(22):4392-400.

Glenn GM, Villar CP, Flyer DC, Bourgeois AL, McKenzie R, Lavker RM , Frech SA. Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: Use of skin pretreatment to disrupt the stratum corneum. Infect Immun. 2007; 75:2163-2170.

McKenzie R, Bourgeois AL, Frech SA, Flyer DC, Bloom A, Kazempour K, Glenn G. Trancutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): Protective efficacy in a double-blind, placebo-controlled challenge study. Vaccine. 2007; 25:3684-3691.

Carpenter CM, Hall ER, Randall R, McKenzie R, Cassels F, Diaz N, Thomas N, Bedford P, Darsley, Gewert MC, Howard RB, Sack DA, Chang HS, Gomes G, Bourgeois, AL. Comparison of the antibody in lymphocyte supernatant (ALS) and ELISPOT assays for detection of mucosal immune responses to antigens of enterotoxigenic Escherichia coli in challenged and vaccinated volunteers. Vaccine. 2006; 24:3709-3718.

McKenzie R, Bourgeois AL, Engstrom F, Hall E, Chang HS, Gomes GJ, Kyle JL, Cassels F, Turner AK, Randall R, Darsley M, Lee C, Bedford P, Shimko J, Sack DA. Comparative safety and immunogencity of two attenuated enterotoxigenic Escherichia coli (ETEC) vaccine strains in healthy adults. Infect Immun. 2006; 74:994-1000.

McKenzie R, Walker RI, Nabors GS, Carpenter CM, Gomes G, Forbes E, Tian JH, Yang HH, Pace JL, Jackson WJ, Bourgeois AL. Safety and immunogencity of an oral, inactivated, whole cell vaccine for Shigella sonnei: Preclinical studies and a phase I trial. Vaccine. 2006; 24:3735-3745.

Taylor DN, McKenzie R, Durbin A, Carpenter C, Atzinger C, Haake R, Bourgeois AL. Rifaximin, a nonabsorbed oral antibiotic, prevents Shigellosis after experimental challenge.Clin Infect Dis. 2006; 42:1283-1288.

Lee LH, Burg E, Baqar S, Bourgeois AL, Burr DH, Ewing CP, Trust TJ, Guerry P. Evaluation of a truncated recombinant flagellin subunit vaccine against Campylobacter jejuni. Infect Immun. 1999; 67:5799-5805.